SLFN11 and cancer: We also aimed to gain mechanistic insights into the link between SLFN11 cancer immunity and DNA-damaging treatment, and most importantly, we investigated whether SLFN11 could represent a relevant prognostic biomarker to platinum-based treatment response in patients with advanced-stage HGSOC.